ClinicalTrials.gg
CompletedNCT05645432Updated Sep 15, 2025Results posted

An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

A Phase 2 interventional study of Brexanolone in Tinnitus, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies in Tinnitus with a site in United States — 16 open to participants now, 19 under way, 1 of them phase 3. Tinnitus · United States.

Enrollment
93rd of 112
10 · median 40
Started
2023
with 4 others
Phase 2
19 of 126
1 open now
Registered
101st of 126
by date

Among the 126 studies in Tinnitus with a site in United States, this one is the 93rd largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2023, is one of 19 in phase 2, and was the 101st registered.

Tinnitus

444 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

Browse Tinnitus studies →

Open to participants now

16 of the 126 studies in Tinnitus with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Tinnitus with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of brexanolone in participants with tinnitus following a single 6-hour continuous intravenous (IV) infusion.

03

Conditions studied

  • Tinnitus

Browse trials for

Keywords

  • Tinnitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has a designated companion for the Clinic Treatment Visit who will drive them when they leave the clinic
  2. Participant is in good physical health and has no findings (excluding tinnitus), as determined by the investigator on medical history and physical examination, including neurologic and mental status examinations, 12-lead (ECG), or clinical laboratory tests
  3. Participant has a diagnosis of subjective, idiopathic, unilateral or bilateral, non-pulsatile tinnitus (e.g., not due to medical disease) of ≥6 months and \<10 years duration
  4. Participant has mild to severe tinnitus distress according to Tinnitus Handicap Inventory (THI) score of 24 to 68 at Screening
  5. Participant is willing and able to safely discontinue the use of central nervous system (CNS) depressants (e.g., opioids and benzodiazepines), antidepressants, anticonvulsants, CNS stimulants (with the exception of caffeine), aspirin, other nonsteroidal anti inflammatory drugs, and aminoglycosides at least 14 days or 5 half-lives (whichever is longer) prior to receiving IP and through completion of the study

Exclusion criteria

Exclusion Criteria:

  1. Participant has history or presence of any neurologic disease or condition, including, but not limited to, unexplained loss of consciousness, seizure disorder including a prior nonfebrile seizure, and closed head trauma with sequelae
  2. Participant has a history of sleep apnea or any clinically significant respiratory conditions that may predispose the participant to hypoxia during the infusion
  3. Participant intends to start or discontinue a pharmacological or nonpharmacological therapy (e.g., psychotherapy, sound therapy, masking, transcranial magnetic stimulation [TMS]) for tinnitus during the course of the study
  4. Participant has currently active and medically significant or uncontrolled hepatic, renal, cardiovascular, pulmonary, gastrointestinal, hematological, immunologic, metabolic disease (hypothyroidism with stable thyroid replacement is acceptable)
  5. Participant's tinnitus can be modulated by maneuvers of the temporomandibular joint, head and neck, eyes, or limbs, or otherwise attributed to somatosensory cause or has had prior otoscopic surgeries or cholesteatoma
  6. Participants has current unilateral or bilateral hearing loss of 30 decibel (dB) or greater (mild hearing loss) in one or more tested frequencies (500 Hertz [Hz], 1000 Hz, 2000 Hz, and 4000 Hz), 60 dB or greater at 6000 Hz and 8000 Hz, asymmetry of 30 dB or greater in two or more tested frequencies, or uses a cochlear implant or hearing aid
  7. Participant has history of chronic otitis media (>3 per year during past 5 years)
  8. Participant has a total score of 15 or greater (i.e., moderately severe) on the Patient Health Questionnaire-9 (PHQ-9) at Screening
  9. Participant has diagnosis of moderate or severe substance use disorder (excluding nicotine dependence) within 12 months of Screening, has a positive screen for drugs of abuse including tetrahydrocannabinol (THC) on Day 1 prior to dosing, or has a positive screen for alcohol on Day 1 prior to dosing
  10. Participant has a known allergy to progesterone, allopregnanolone, or any IP
  11. Participant has had exposure to another drug or device within 30 days or 5 half-lives of the investigational drug, whichever is longer, prior to the Day 1 visit
  12. Participant has a history of suicidal behavior within 2 years or answers "YES" to Questions 3, 4, or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or at Day 1 or is currently at risk of suicide in the opinion of the investigator
  13. Participant has donated 1 or more units (1 unit = 450 milliliter [mL]) of blood or experienced acute loss of an equivalent amount of blood within 60 days prior to Day 1
  14. Participant has any condition, comorbidity, or lifestyle consideration that in the opinion of the investigator would limit or interfere with the participant's ability to complete or partake in the study
  15. Participant is unwilling or unable to comply with study procedures and the required training during the Baseline Period. The participant must complete 10 VAS assessments remotely prior to Day 1
  16. Participant is unable to complete participation in the study, e.g., due to preplanned event including elective surgery
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Brexanolone

    Participants will receive a 6-hour single continuous intravenous (IV) infusion of brexanolone at 30 micrograms per kilogram per hour (mcg/kg/hour) for 0 to 0.5 hours, at 60 mcg/kg/hour for 0.5 to 1 hour, and at 90 mcg/kg/hour for 1 to 6 hours, on Day 1 of the Treatment Period.

    Drug: Brexanolone

Interventions

  • Brexanolone IV infusion

    Also known as: Allopregnanolone, ZULRESSO®, SAGE-547

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of brexanolone, or any worsening of a pre-existing medical condition/adverse event with onset after the start of brexanolone and throughout the study.

    Time frame: Up to Day 15

Secondary outcomes

  1. Change From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Loudness (VAS-L) Ratings

    VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

    Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1

  2. Change From Baseline (Model Based) to Hour 6 of Infusion in VAS-L Ratings

    VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A Mixed Model Repeated Measures (MMRM) with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

    Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1

  3. Change From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Annoyance (VAS-A) Ratings

    VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

    Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1

  4. Change From Baseline (Model Based) to Hour 6 of Infusion in VAS-A Ratings

    VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

    Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1

  5. Change From Baseline (Observed Value) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days

    VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

    Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1

  6. Change From Baseline (Model Based) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days

    VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

    Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1

  7. Change From Baseline (Observed Value) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days

    VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

    Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1

  8. Change From Baseline (Model Based) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days

    VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

    Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1

07

Results

Posted Dec 12, 2024

Participant flow

Participants were enrolled at one active clinical site in the United States from 10 May 2023 to 21 November 2023.

Participant flow — Overall Study
MilestoneBrexanolone
Started10
Completed9
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAE)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of brexanolone, or any worsening of a pre-existing medical condition/adverse event with onset after the start of brexanolone and throughout the study.

Time frame:
Up to Day 15
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAE)
ParticipantsBrexanolone
Number of Participants With Treatment-Emergent Adverse Events (TEAE)1
SecondaryChange From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Loudness (VAS-L) Ratings

VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

Time frame:
Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Reported as:
Mean · score on a scale
Change From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Loudness (VAS-L) Ratings
score on a scaleBrexanolone
Change at Day 1, Hour 0.5-3.1 ± 8.33
Change at Day 1, Hour 1-8.1 ± 14.13
Change at Day 1, Hour 2-7.2 ± 14.41
Change at Day 1, Hour 3-11.2 ± 14.54
Change at Day 1, Hour 4-15.4 ± 16.26
Change at Day 1, Hour 5-15.7 ± 15.72
Change at Day 1, Hour 6-12.8 ± 9.32
SecondaryChange From Baseline (Model Based) to Hour 6 of Infusion in VAS-L Ratings

VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A Mixed Model Repeated Measures (MMRM) with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

Time frame:
Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Reported as:
Least squares mean · score on a scale
Change From Baseline (Model Based) to Hour 6 of Infusion in VAS-L Ratings
score on a scaleBrexanolone
Change at Day 1, Hour 0.5-3.10 ± 2.486
Change at Day 1, Hour 1-8.10 ± 4.441
Change at Day 1, Hour 2-7.20 ± 4.472
Change at Day 1, Hour 3-11.20 ± 4.474
Change at Day 1, Hour 4-15.40 ± 5.043
Change at Day 1, Hour 5-15.70 ± 4.826
Change at Day 1, Hour 6-12.80 ± 3.013
SecondaryChange From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Annoyance (VAS-A) Ratings

VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

Time frame:
Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Reported as:
Mean · score on a scale
Change From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Annoyance (VAS-A) Ratings
score on a scaleBrexanolone
Change at Day 1, Hour 0.5-7.6 ± 13.45
Change at Day 1, Hour 1-9.8 ± 18.74
Change at Day 1, Hour 2-16.6 ± 28.68
Change at Day 1, Hour 3-16.9 ± 20.00
Change at Day 1, Hour 4-21.3 ± 28.07
Change at Day 1, Hour 5-22.0 ± 27.71
Change at Day 1, Hour 6-22.3 ± 20.92
SecondaryChange From Baseline (Model Based) to Hour 6 of Infusion in VAS-A Ratings

VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.

Time frame:
Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Reported as:
Least squares mean · score on a scale
Change From Baseline (Model Based) to Hour 6 of Infusion in VAS-A Ratings
score on a scaleBrexanolone
Change at Day 1, Hour 0.5-7.60 ± 4.088
Change at Day 1, Hour 1-9.80 ± 5.193
Change at Day 1, Hour 2-16.60 ± 8.108
Change at Day 1, Hour 3-16.90 ± 5.790
Change at Day 1, Hour 4-21.30 ± 7.980
Change at Day 1, Hour 5-22.00 ± 7.882
Change at Day 1, Hour 6-22.30 ± 5.167
SecondaryChange From Baseline (Observed Value) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days

VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

Time frame:
Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Reported as:
Mean · score on a scale
Change From Baseline (Observed Value) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days
score on a scaleBrexanolone
Change at Day 2-17.56 ± 19.125
Change at Day 3-17.51 ± 22.231
Change at Day 4-15.61 ± 20.084
Change at Day 5-16.76 ± 22.388
Change at Day 6-16.96 ± 22.235
Change at Day 7-11.31 ± 19.509
SecondaryChange From Baseline (Model Based) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days

VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

Time frame:
Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Reported as:
Least squares mean · score on a scale
Change From Baseline (Model Based) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days
score on a scaleBrexanolone
Change at Day 2-17.56 ± 6.769
Change at Day 3-17.51 ± 8.035
Change at Day 4-15.61 ± 6.805
Change at Day 5-16.76 ± 8.064
Change at Day 6-16.96 ± 7.721
Change at Day 7-11.31 ± 7.330
SecondaryChange From Baseline (Observed Value) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days

VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

Time frame:
Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Reported as:
Mean · score on a scale
Change From Baseline (Observed Value) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days
score on a scaleBrexanolone
Change at Day 2-19.41 ± 19.492
Change at Day 3-16.01 ± 21.161
Change at Day 4-13.41 ± 23.037
Change at Day 5-15.16 ± 26.075
Change at Day 6-11.51 ± 27.493
Change at Day 7-7.61 ± 23.659
SecondaryChange From Baseline (Model Based) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days

VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.

Time frame:
Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Reported as:
Least squares mean · score on a scale
Change From Baseline (Model Based) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days
score on a scaleBrexanolone
Change at Day 2-19.41 ± 7.266
Change at Day 3-16.01 ± 8.111
Change at Day 4-13.41 ± 8.288
Change at Day 5-15.16 ± 8.716
Change at Day 6-11.51 ± 9.523
Change at Day 7-7.61 ± 8.078

Adverse events

Collected over Up to Day 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexanolone0/10 (0%)0/10 (0%)1/10 (10%)
Most frequent other events
Most frequent other events
EventBrexanolone
TinnitusEar and labyrinth disorders1/10

Baseline characteristics

Safety set included all participants who received any amount of brexanolone.

Age, Continuous
Age, Continuous(years)Brexanolone
Mean48.8 ± 9.96
Sex: Female, Male
Sex: Female, Male(Participants)Brexanolone
Female7
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brexanolone
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brexanolone
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White4
More than one race0
Unknown or Not Reported0
08

Study locations

2 sites
  • Sage Investigational Site
    Atlanta, Georgia 30331, United States
  • Sage Investigational Site
    Iowa City, Iowa 52242, United States
09

References and documents

Publications

  • Watson LS, O'Donnell P, Bankole K, Toubouti Y, Tyler RS, Johannesen JK. An open-label, proof-of-mechanism trial evaluating a neuroactive steroid GABA modulator in tinnitus. Front Neurol. 2025 Nov 18;16:1662226. doi: 10.3389/fneur.2025.1662226. eCollection 2025. PubMed 41341514 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Nov 2023, 6 months.

Results were first posted in Dec 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
May 10, 2023
Primary completionActual
Nov 21, 2023
CompletionActual
Nov 21, 2023
Results first posted
Dec 12, 2024
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05645432
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
May 10, 2023
Primary completion
Nov 21, 2023
Completion
Nov 21, 2023
Results posted
Dec 12, 2024
Last update
Sep 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion